August 30, 2018
Tobacco Control just published “IQOS: examination of Philip Morris International’s claim of reduced exposure” and “Assessment of industry data on pulmonary and immunosuppressive effects of IQOS” that provide insights based on the information PMI provided to FDA as part of its Modified Risk Tobacco Product IQOS.
PMI is making a big deal about the fact that IQOS delivers lower levels of many toxins than conventional cigarettes. They ignore the fact that their own data show higher levels – sometimes much higher levels – of others.
Other information shows that IQOS generates significant pulmonary harm, including adverse effects on the immune system in the lung that compromise lungs’ ability to resist infection. These effects do not appear to significantly different from conventional cigarettes.
These results are consistent with the other papers that concluded that the adverse health effects of IQOS are not all that different from cigarettes.
August 24, 2018
Tobacco Control just published two peer reviewed papers based on close reads of the raw data buried in Philip Morris International's application to FDA to sell IQOS as a reduced risk product.
As the title " PMI’s own in vivo clinical data on biomarkers of potential harm in Americans show that IQOS is not detectably different from conventional cigarettes" indicates, PMI's own data shows that the measures of health impact that IQOS has are not statistically different from conventional cigarettes. (I wrote a piece on The Conversation summarizing these results in simple English a few months ago.)
August 24, 2018
This letter to TPSAC summarizes the UCSF TCORS' public comments to FDA on the RJR application to FDA to be allowed to market Camel Snus as less dangerous. The tracking number in regulations.gov is 1k2-9510-dtqo. A PDF of the letter (including all the individual comments) is available here.
August 23, 2018
Tobacco Products Scientific Advisory Committee
August 24, 2018
My colleagues and I at UCSF have submitted this public comment to FDA on RJR's application to market Camel Snus as less dangerous. The tracking number on regulations.gov is 1k2-9510-3515. A PDF of the comment is here.
Docket Number: FDA-2017-N-4678-0001
Clinical Trials and Observational Epidemiology Indicate that Allowing Snus to be Marketed with Modified Risk Claims is Unlikely to Confer Population Benefit and May Cause Harm by Depressing Smoking Cessation
August 24, 2018
My colleagues at UCSF have submitted this public comment to FDA regarding RJR's application to sell Camel Snus as a reduced risk product. The tracking number at regulations.gov is 1k2-9510-3zjn. A PDF of the comment is here.
Docket number: FDA-2017-N-4678-0001
Reynolds’ own data do not support their claim that because exclusive users of Camel Snus experience lower levels of exposure to some toxicants, they will reduce their risk of harm from lung cancer, oral cancer, respiratory disease, and heart disease